Keeping pace with Immuno-oncology research breakthroughs and biomarker identification
Join us from 11am-12pm.
May 04, 2016 - May 04, 2016 | 11:00 - 12:00 Add to Calendar
About This EventThe excitement surrounding Immuno-oncology is being driven by results seen in the clinic. For example, after being treated with immune-boosting Keytruda, 91-year-old Jimmy Carter, former US president, is free from the 4 melanoma lesions uncovered by a brain MRI, and cancer-free overall. More recently, re-engineered T-cells were introduced to 35 terminally ill leukemia patients and 94% went into full remission. These treatments can potentially be made more efficacious using NGS technology that would accelerate biomarker identification and bring down costs for research subject screening and safety monitoring.
Among these technologies is RNA-Seq, a flexible sequencing assay that enables multiple applications with one assay from a single sample. Because of this flexibility, legacy RNA-Seq datasets can be revisited for new insights to keep pace with today's rapid advance of therapeutic breakthroughs. When prepared and analyzed correctly, RNA-Seq provides high-throughput, comprehensive, direct measurement of functionally relevant molecular processes. Here, we summarize the clinical relevance of RNA-Seq, when and how to use expression profiling economically, some common challenges and associated remedies.
Applications to be covered include:
- Expression profiling
- Measuring effective mutational load
- Calling HLA alleles
- The possibility to interrogate the immune T- and B-cell receptor repertoire
We also introduce practical applications of these data to the identification of biomarkers for drug development and safety monitoring.
By attending this webinar you will:
- Learn more about key applications for RNA-Seq in Immuno-oncology
- Learn how RNA-Seq provides high-throughput, comprehensive, direct measurement of functionally relevant molecular processes
- Learn how legacy RNA-Seq datasets can be revisited for new insights to keep pace with today's rapid advance of therapeutic breakthroughs
- Adrian Benjamin, Ph.D. , Commercial Development Manager, Oncology at Illumina
- Kimberly Robasky, Ph.D., Associate Director, Lead Scientist, Bioinformatics and Clinical Systems Product Manager, Genomics at Q2 Solutions